🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial

RecruitingPhase 2Ages 18 Years - 70 YearsFemaleWomen's Hospital School Of Medicine Zhejiang Univ…
NCT07167160 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Efficacy evaluation of camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Patients with cervical cancer staged FIGO2018 IIIC1p or IIIC2p after radical surgery; 2. Positive PD-L1 expression; 3. ECOG score ≤1 Exclusion Criteria: 1. Positive parametrium or surgical margin; 2. Incomplete radical surgery; 3. Residual target lesions; 4. Active autoimmune disease or autoimmune disease requiring systemic treatment; 5. Previous treatment with immune checkpoint inhibitors.
💊

What it tests

  • Camrelizumab combined with chemotherapy
📍

Where

1 site
Women's Hospital, School of Medicine, Zhejiang University
Hangzhou, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy